A 33-YEAR-OLD MAN was being treated for meningitis with amphotericin B through an intraventricular reservoir. Despite pretreatment medications, he experienced adverse reactions from the infusion and his infection progressed to the lumbosacral vertebral area. The intraventricular therapy was switched to IN. therapy, but he continued to have infusion-related adverse reactions.
Because of renal insufficiency, the patient was switched to IN. liposomal amphotericin B (Abelcet). This drug didn't cause infusion problems, but his serum creatinine remained elevated at 3.5 mg/dl (normal, 0.5 to 1.5 mg/dl). He took this second amphotericin product for 6 weeks, then was switched to IN. amphotericin B cholesteryl (Amphotec). After receiving the first dose, he felt severe back pain, which resolved in 5 minutes. The infusion rate was slowed, but within an hour, the patient developed swelling of the lips, hemiparesis on the left side, and difficulty breathing.
He was rushed to the ED and treated. The swelling quickly resolved and the hemiparesis abated within 24 hours.
What went wrong?
The physicians reporting this case believe the patient experienced an anaphylactic reaction to amphotericin B. The drug's manufacturer calls the patient's response an infusion reaction. Several formulations of amphotericin B are available, and patients may react differently to different forms. Rare reports of anaphylaxis have been associated with all products containing amphotericin B.
What precautions can you take?
Monitor your patient closely when switching from one form of amphotericin B to another, and during test doses.
Monitor the patient's creatinine level carefully and frequently during therapy; renal damage usually is reversible if therapy stops with the first sign of dysfunction.
Make sure the patient is stable on therapy before infusing amphotericin B in a home health care setting.
Sources: "Anaphylaxis upon Switching Lipid-containing Amphotericin B Formulations," Clinical Infectious Diseases, C. Kauffman and S. Wiseman, May 1998; "Anaphylaxis upon Switching Lipid-containing Amphotericin B Formulations [letter]," Clinical Infectious Diseases, J. Cronin and R. Barron, June 1999.
Dr. Shuster is associate professor of clinical pharmacology, Temple University, and clinical pharmacist, Medical College of Pennsylvania Hospital, both in Philadelphia, Pa. Send examples of adverse drug reactions to: Joel Shuster, PharmD, The Institute for Safe Medication Practices, 1800 Byberry Rd., Suite 810, Huntingdon Valley, PA 19006. E-mail: joel.shuster@tenethealth.com. Fax: 215-914-1492.
If we publish your item (anonymously), we'll pay you $25.
Copyright Springhouse Corporation Nov 2000
Provided by ProQuest Information and Learning Company. All rights Reserved